[go: up one dir, main page]

SV2006002187A - Indazoles utiles para tratamientos de enfermedades cardiovasculares ref.wyth0089-504(am101590) - Google Patents

Indazoles utiles para tratamientos de enfermedades cardiovasculares ref.wyth0089-504(am101590)

Info

Publication number
SV2006002187A
SV2006002187A SV2005002187A SV2005002187A SV2006002187A SV 2006002187 A SV2006002187 A SV 2006002187A SV 2005002187 A SV2005002187 A SV 2005002187A SV 2005002187 A SV2005002187 A SV 2005002187A SV 2006002187 A SV2006002187 A SV 2006002187A
Authority
SV
El Salvador
Prior art keywords
useful
wyth0089
indazols
treatments
cardiovascular diseases
Prior art date
Application number
SV2005002187A
Other languages
English (en)
Inventor
Robert J Steffan
Edward M Matelan
Stephen M Bowen
John W Ullrich
Jay E Wrobel
Edouard Zamaratski
Lars Kruger
Hedemyr Annabel L Olsen
Aiping Cheng
Tomas Hansson
Rayomand J Unwalla
Christopher P Miller
Patrik P Rhoennstad
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of SV2006002187A publication Critical patent/SV2006002187A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

LA PRESENTE INVENCION PROVEE COMPUESTOS DE LA FORMULA (I) O, VER FORMULA,LAS CUALES SON UTILES PARA EL TRATAMIENTO O INHIBICION DE LAS ENFERMEDADES MEDIADES POR LXR
SV2005002187A 2004-08-03 2005-08-08 Indazoles utiles para tratamientos de enfermedades cardiovasculares ref.wyth0089-504(am101590) SV2006002187A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59857304P 2004-08-03 2004-08-03
US66973705P 2005-04-08 2005-04-08

Publications (1)

Publication Number Publication Date
SV2006002187A true SV2006002187A (es) 2006-09-14

Family

ID=35311622

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2005002187A SV2006002187A (es) 2004-08-03 2005-08-08 Indazoles utiles para tratamientos de enfermedades cardiovasculares ref.wyth0089-504(am101590)

Country Status (21)

Country Link
US (1) US7592363B2 (es)
EP (2) EP1773781A2 (es)
JP (1) JP2008509138A (es)
KR (1) KR20070045226A (es)
CN (1) CN101213194A (es)
AR (1) AR050279A1 (es)
AU (1) AU2005271737A1 (es)
BR (1) BRPI0514017A (es)
CA (1) CA2575180A1 (es)
CR (1) CR8888A (es)
EC (1) ECSP077223A (es)
GT (1) GT200500208A (es)
IL (1) IL180759A0 (es)
MX (1) MX2007000791A (es)
NO (1) NO20070933L (es)
PA (1) PA8640701A1 (es)
PE (1) PE20060417A1 (es)
RU (1) RU2007101488A (es)
SV (1) SV2006002187A (es)
TW (1) TW200605886A (es)
WO (1) WO2006017384A2 (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3658525A (en) * 1970-12-03 1972-04-25 Eastman Kodak Co Reversal color photographic processes
TW200409759A (en) * 2002-09-25 2004-06-16 Wyeth Corp Substituted 4-(indazol-3-yl)phenols
ES2438739T3 (es) 2005-06-28 2014-01-20 Daiichi Sankyo Company, Limited Procedimiento de prueba de ligando LXR
WO2008036238A2 (en) * 2006-09-19 2008-03-27 Wyeth Use of lxr modulators for the prevention and treatment of skin aging
MX2009002794A (es) * 2006-09-19 2009-03-30 Wyeth Corp Uso de agonistas lxr para el tratamiento de osteoartritis.
ITMI20062230A1 (it) * 2006-11-22 2008-05-23 Acraf Composto 2-alchil-indazolico procedimento per preparalo e composizione farmaceutica che lo comprende
JPWO2008093639A1 (ja) * 2007-01-29 2010-05-20 武田薬品工業株式会社 ピラゾール化合物
US9085566B2 (en) 2007-02-02 2015-07-21 Baylor College Of Medicine Compositions and methods for the treatment of metabolic and related disorders
US9187485B2 (en) 2007-02-02 2015-11-17 Baylor College Of Medicine Methods and compositions for the treatment of cancer and related hyperproliferative disorders
US9233941B2 (en) 2007-02-02 2016-01-12 Baylor College Of Medicine Methods and compositions for the treatment of body weight related disorders
AU2008214095B2 (en) 2007-02-02 2014-07-10 Baylor College Of Medicine Compositions and methods for the treatment of metabolic disorders
US9212179B2 (en) 2007-02-02 2015-12-15 Baylor College Of Medicine Compositions and methods for the treatment of metabolic disorders
US8835437B2 (en) 2007-06-08 2014-09-16 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
US8633197B2 (en) * 2007-06-08 2014-01-21 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
CA2687754C (en) * 2007-06-08 2015-12-08 Janssen Pharmaceutica N.V. Piperidine, piperazine derivatives for use as dgat inhibitors
JO2972B1 (en) 2007-06-08 2016-03-15 جانسين فارماسوتيكا ان. في Piperidine / piperazine derivatives
US20100331333A1 (en) * 2007-12-21 2010-12-30 Wyeth Llc Imidazo [1,2-B] Pyridazine Compounds
BRPI0822239A2 (pt) * 2007-12-21 2015-06-30 Wyeth Llc Composto de pirazolo[1,5-a] pirimidina
US20090209601A1 (en) * 2008-02-15 2009-08-20 Wyeth Use of rxr agonists for the treatment of osteoarthritis
UY31863A (es) * 2008-06-05 2010-01-05 Janssen Pharmaceutica Nv Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar
MX2012006994A (es) 2009-12-18 2012-07-03 Mitsubishi Tanabe Pharma Corp Agente antiplaquetas novedoso.
JP2013532734A (ja) * 2010-08-04 2013-08-19 ユニバーシティ オブ バージニア パテント ファウンデーション 炎症性疾患を治療するための組成物及び方法
KR101901741B1 (ko) 2010-09-07 2018-10-01 서울대학교산학협력단 세스터터핀 화합물 및 이들 물질의 용도
EP2487159A1 (en) 2011-02-11 2012-08-15 MSD Oss B.V. RorgammaT inhibitors
US9487506B2 (en) 2011-04-13 2016-11-08 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
JP5959330B2 (ja) * 2011-06-17 2016-08-02 田辺三菱製薬株式会社 新規抗血小板薬
EP2794561B1 (en) 2011-12-21 2018-08-22 Allergan, Inc. Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response
SG10201607345YA (en) 2012-03-02 2016-11-29 Ralexar Therapeutics Inc Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions
WO2014026329A1 (en) 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. N-alkylated indole and indazole compounds as rorgammat inhibitors and uses thereof
WO2014026327A1 (en) 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 4-heteroaryl substituted benzoic acid compounds as rorgammat inhibitors and uses thereof
WO2014026330A1 (en) 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
WO2014026328A1 (en) * 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 3-cyclohexenyl substituted indole and indazole compounds as rorgammat inhibitors and uses thereof
CN104151300B (zh) * 2013-05-15 2018-07-13 中国医学科学院医药生物技术研究所 一组2,3-二取代的苯并喹唑啉类的肝x受体的激动剂及用途
BR112016004904B1 (pt) 2013-09-04 2023-01-24 Ellora Therapeutics, Inc. Compostos moduladores de receptor x do fígado (lxr), seu uso e composição farmaceutica compreendendo os mesmos
CA2923178A1 (en) 2013-09-04 2015-03-12 Alexar Therapeutics, Inc. Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions
EP3080101A1 (en) 2013-12-10 2016-10-19 Cleave Biosciences, Inc. Monocyclic pyrimidine/pyridine compounds as inhibitors of p97 complex
AU2015204572B2 (en) 2014-01-10 2020-07-30 Inspirna, Inc. LXR agonists and uses thereof
CN106458996B (zh) 2014-01-20 2020-11-03 克里弗生物科学公司 作为p97复合物的抑制剂的稠合嘧啶
US10583102B2 (en) 2014-10-06 2020-03-10 The Johns Hopkins University Targeting liver nuclear receptors as a treatment for wilson disease
CA2975997A1 (en) 2015-02-11 2016-08-18 Merck Sharp & Dohme Corp. Substituted pyrazole compounds as rorgammat inhibitors and uses thereof
CN109234295B (zh) * 2015-07-03 2022-09-23 赣南师范大学 一种微生物体内基于脂肪酸合成脂肪醇乙酸酯的方法
CN105153125A (zh) * 2015-09-29 2015-12-16 青岛友诚高新技术有限公司 一种可用于制备保护心肌缺血药物的化合物及其制备方法、用途
EP3368535B1 (en) 2015-10-27 2020-12-02 Merck Sharp & Dohme Corp. Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof
WO2017075182A1 (en) 2015-10-27 2017-05-04 Merck Sharp & Dohme Corp. Substituted indazole compounds as rorgammat inhibitors and uses thereof
JP2018531957A (ja) 2015-10-27 2018-11-01 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ＲＯＲγＴ阻害薬としての置換二環式ピラゾール化合物及びその使用
AU2017207291B2 (en) 2016-01-11 2023-06-15 The Rockefeller University Methods for the treatment of myeloid derived suppressor cells related disorders
CN109153667B (zh) * 2016-02-24 2021-04-02 阿塞西翁制药公司 新型钾通道抑制剂
AU2018373028A1 (en) 2017-11-21 2020-04-30 Inspirna, Inc. Polymorphs and uses thereof
TWI748194B (zh) 2018-06-28 2021-12-01 德商菲尼克斯 Ｆｘｒ有限責任公司 含有雙環核心部分之新穎lxr調節劑
CA3120970A1 (en) 2018-11-26 2020-06-04 Denali Therapeutics Inc. Methods for treating dysregulated lipid metabolism
SG11202112994WA (en) * 2019-05-31 2021-12-30 Janssen Pharmaceutica Nv SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE
JP2022541013A (ja) 2019-07-15 2022-09-21 ノバルティス アーゲー 肝臓ｘ受容体アゴニストでマイボーム腺機能不全を治療するための方法
WO2021022061A1 (en) * 2019-07-30 2021-02-04 Oregon State University Aryl hydrocarbon receptor activators
RS65646B1 (sr) 2019-12-13 2024-07-31 Inspirna Inc Soli metala i njihove upotrebe
CN115947690B (zh) * 2022-12-13 2025-04-08 安徽医科大学 一种吲唑分子砌块的制备方法及其在药物合成中的应用
CN116514669B (zh) * 2023-04-12 2025-02-28 上海灵瑞医药有限公司 2-氯-5-苯氧基苯胺的合成方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3152135A (en) * 1962-11-02 1964-10-06 Warner Lambert Pharmaceutical Heterocyclic substituted indazole compounds and process therefor
US3541110A (en) * 1967-01-20 1970-11-17 American Home Prod Indazole-5-sulfonamides
IL84944A (en) 1987-01-19 1992-02-16 Ici Plc Pharmaceutical compositions containing 1,2-dihydro-3h-indazolone derivatives,some new such compounds and their preparation
US5321028A (en) * 1988-09-02 1994-06-14 Janssen Pharmaceutica N.V. Antihypertensive 3-piperidinyl-indazole derivatives
FR2673628B1 (fr) * 1991-03-07 1993-07-09 Esteve Labor Dr Procede de preparation de derives d'aryl (ou heteroaryl)-piperazinyl-butyl-azoles.
JPH04282372A (ja) 1991-03-08 1992-10-07 Nissan Chem Ind Ltd インダゾール誘導体の製造方法
US6005109A (en) * 1997-10-30 1999-12-21 Pflizer Inc. Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity
JPH0717950A (ja) 1993-06-29 1995-01-20 Fuji Photo Film Co Ltd アゾ化合物の製造方法と得られたアゾ化合物を用いたインダゾールの製造方法
DE19612291A1 (de) 1996-03-28 1997-10-02 Bernhard K Prof Dr Dr Keppler Arzneimittelzubereitungen enthaltend tumorhemmend wirkende Ruthenium(III)-Komplexe
DE19744026A1 (de) * 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
DE69842143D1 (de) * 1997-10-24 2011-04-07 Nissan Chemical Ind Ltd Sulfamoyl-verbindungen und bakterizide für landwirtschaft oder gartenbau
GB9824310D0 (en) 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase
DE60005808T2 (de) 1999-04-20 2004-09-23 Syngenta Ltd., Guildford Pestizide indazol- oder benzotriazolderivate
US6632815B2 (en) * 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
CN1390206A (zh) 1999-09-17 2003-01-08 千嬉药品公司 因子Xa的抑制剂
WO2001058869A2 (en) 2000-02-11 2001-08-16 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases
AU2001250783A1 (en) 2000-02-29 2001-09-12 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
AU2001273040A1 (en) 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
WO2002016348A1 (en) 2000-08-09 2002-02-28 Astrazeneca Ab Antiangiogenic bicyclic derivatives
DE10046029A1 (de) * 2000-09-18 2002-03-28 Bayer Ag Indazole
WO2003004488A1 (en) * 2001-07-03 2003-01-16 Chiron Corporation Indazole benzimidazole compounds as tyrosine and serine/threonine kinase inhibitors
WO2003024969A1 (en) * 2001-09-14 2003-03-27 Merck & Co., Inc. Tyrosine kinase inhibitors
US20030109550A1 (en) 2001-09-19 2003-06-12 Michael Clare Substituted indazole compounds for the treatment of inflammation
CA2465247C (en) * 2001-10-26 2010-05-18 Aventis Pharmaceuticals Inc. Benzimidazoles and analogues and their use as protein kinases inhibitors
FR2836915B1 (fr) 2002-03-11 2008-01-11 Aventis Pharma Sa Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
TW200409759A (en) * 2002-09-25 2004-06-16 Wyeth Corp Substituted 4-(indazol-3-yl)phenols
MXPA05005794A (es) * 2002-12-02 2005-08-16 Hoffmann La Roche Derivados de indazol como antagonistas del factor de liberacion de corticotropina.
JP2007502257A (ja) 2003-08-14 2007-02-08 エフ．ホフマン−ラ　ロシュ　アーゲー γアミノ酪酸作動性モジュレーター
US6984652B2 (en) * 2003-09-05 2006-01-10 Warner-Lambert Company Llc Gyrase inhibitors

Also Published As

Publication number Publication date
IL180759A0 (en) 2007-06-03
US7592363B2 (en) 2009-09-22
CA2575180A1 (en) 2006-02-16
PA8640701A1 (es) 2006-09-08
AU2005271737A1 (en) 2006-02-16
KR20070045226A (ko) 2007-05-02
TW200605886A (en) 2006-02-16
CN101213194A (zh) 2008-07-02
PE20060417A1 (es) 2006-06-13
AR050279A1 (es) 2006-10-11
WO2006017384A2 (en) 2006-02-16
EP1773781A2 (en) 2007-04-18
MX2007000791A (es) 2007-03-23
WO2006017384A3 (en) 2007-09-20
RU2007101488A (ru) 2008-09-10
JP2008509138A (ja) 2008-03-27
GT200500208A (es) 2006-03-02
US20060030612A1 (en) 2006-02-09
EP2295429A1 (en) 2011-03-16
BRPI0514017A (pt) 2008-05-27
ECSP077223A (es) 2007-03-29
CR8888A (es) 2007-08-28
NO20070933L (no) 2007-03-28

Similar Documents

Publication Publication Date Title
SV2006002187A (es) Indazoles utiles para tratamientos de enfermedades cardiovasculares ref.wyth0089-504(am101590)
CR8410A (es) Quinolinas utiles en el tratamiento de enfermedades cardiovasculares
CR9866A (es) Novedosos derivados de 1-aza-bicicloalquilo para el tratamiento de trastornos psicoticos y neurodegenerativos
NO20092711L (no) Metoder for anvendelse av cyclopaminanaloger
CR9034A (es) Preparacion y uso de derivados de acido bifenil-4-il-carbonilamino para el tratamiento de la obesidad
EA201170872A1 (ru) Ингибиторы протеинкиназы
ECSP088536A (es) DERIVADOS DE PIRIDO-, PIRAZO- Y PIRIMIDO-PIRIMIDINA COMO INHIBIDORES DE mTOR
CR10304A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
SV2007002146A (es) Difenilimidazopirimidina e imidazol aminas como inhibidores de beta-secretasa ref. am101727
EA200501771A1 (ru) Лиганды каннабиноидных рецепторов и их применения
UY32123A (es) Derivados de n - (sustituido) - 4 - (but-2-iniloxi) - benzamida, sus racematos, diastereòmeros, enantiòmeros y las sales de los mismos y aplicaciones
ECSP088561A (es) Derivados de pirimidinil-aril-urea que son inhibidores de fgf
ECSP088625A (es) Compuestos para el tratamiento de trastornos inflamatorios
ECSP088210A (es) Bencimidazoles sustituidos y métodos de preparación
ECSP077360A (es) Compuestos sulfonamida
EA200700225A1 (ru) Аналоги тетрапептида
CR9347A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
UY30723A1 (es) Compuestos de biciclocarboxiamida sustituidos
UY30627A1 (es) Inhibidores de metaloproteasas derivados de heterociclos
DOP2005000025A (es) Compuestos de heteroaril- y fenilsulfamoilo sustituidos
EA201170344A1 (ru) Азаиндольные ингибиторы iap
PA8667201A1 (es) Nuevos compuestos farmaceuticos
BRPI0509660A (pt) compostos de beta-carbolina de utilidade no tratamento de doenças inflamatórias
ATE458487T1 (de) Tumorbehandlung mit gliotoxin-derivaten

Legal Events

Date Code Title Description
FD Lapse